Evidence map›Paper›PMID 42127347›Full record

ArticleNeurology2026

Risk of Myasthenia Gravis Exacerbation During Pregnancy and Postpartum: A Nationwide Cohort Study.

Laura O'Connor, Katja Gabrysch, Anna-Karin Wikström, Anna Rostedt Punga

Abstract read
In one paragraph

Article in Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Laura O'ConnorDepartment of Medical Sciences, Uppsala University, Sweden.
Katja GabryschUppsala Clinical Research Center, Uppsala University, Sweden; and.ORCID 0009-0003-4234-8814
Anna-Karin WikströmDepartment of Women's and Children's Health, Uppsala University, Sweden.ORCID 0000-0001-6431-3303
Anna Rostedt PungaDepartment of Medical Sciences, Uppsala University, Sweden.ORCID 0000-0002-2178-9413

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesThe impact of pregnancy on the clinical course of myasthenia gravis (MG) remains uncertain, with existing evidence mainly derived from small case series. Using nationwide longitudinal register data, we aimed to assess the risk of MG exacerbation during pregnancy and up to 1 year postpartum.

methodsIn this population-based cohort study, we included women with MG recorded in the Swedish National MG Register who had singleton pregnancies documented in the Medical Birth Register after MG diagnosis (1987-2019). The exposure was pregnancy, and the outcome was MG exacerbation. The primary outcome measure was hospital admissions with MG during pregnancy and the postpartum year, compared with the year preceding pregnancy. Cox proportional hazards models estimated hazard ratios (HRs), adjusting for disease duration and prior thymectomy. The secondary outcome measure was changes in immunosuppressive MG medications during pregnancy and postpartum.

resultsWe identified 112 women with MG (median age 30 years) with 176 singleton pregnancies. During pregnancy, women were not more likely to be hospitalized for MG than in the prepregnancy year (HR 0.74, 95% CI 0.39-1.41), and there was no increased risk of longer hospital admissions (HR 0.83, 95% CI 0.36-1.88). The postpartum period was associated with an increased risk of prolonged MG admissions during the first 3 months (HR 5.02, 95% CI 1.66-15.24), with a similar risk observed throughout the first 12 months postpartum (HR 4.52, 95% CI 1.26-16.14). During pregnancy, immunosuppressive MG medications were reduced or discontinued in 13 pregnancies and increased in 6. Postpartum, medications were initiated or escalated in 10 pregnancies and reduced in none. The risk of prolonged MG admissions was higher in periods outside of pregnancy compared with the prepregnancy year (HR 2.95, 95% CI 0.84-10.43), suggesting that women conceive during periods of relative disease stability. DISCUSSION: Pregnancy was not associated with an increased risk of MG exacerbation. The postpartum period was linked to more severe or prolonged exacerbations in a minority of women, highlighting the importance of close monitoring after delivery. Milder exacerbations not requiring hospitalization or clear medication escalation may have been underestimated, underscoring the need for larger prospective international studies that include detailed clinical data.

Indexed as

Myasthenia GravisPostpartum PeriodPregnancy ComplicationsAdultCohort StudiesDisease ProgressionFemaleHospitalizationHumansImmunosuppressive AgentsLongitudinal StudiesPregnancyRegistriesRisk FactorsSwedenImmunosuppressive Agents

Identifiers

PMID42127347
PMCPMC13225240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.